Xiling Shen

Shen

Adjunct Professor in the Department of Pathology

Dr. Shen’s research interests lie at precision medicine and systems biology. His lab integrates engineering, computational and biological techniques to study cancer, stem cells, microbiota and the nervous system in the gut. This multidisciplinary work has been instrumental in initiating several translational clinical trials in precision therapy. He is the director of the Woo Center for Big Data and Precision Health (DAP) and a core member of the Center for Genomics and Computational Biology (GCB).

Appointments and Affiliations

  • Adjunct Professor in the Department of Pathology

Contact Information

Education

  • Ph.D. Stanford University, 2008
  • M.Sc. Stanford University, 2001
  • B.Sc. Stanford University, 2001

Research Interests

Precision medicine for cancer, regeneration, microbiome, and gut-brain axis. Multi-omics approaches including organoid, epigenetics, CRISPR, single-cell, metabolomics, machine learning, droplet microfluidics, humanized immune model and intravital imaging.

Courses Taught

  • BME 590: Special Topics in Biomedical Engineering
  • BME 791: Graduate Independent Study
  • BME 792: Continuation of Graduate Independent Study

In the News

Representative Publications

  • Giroux, NS; Ding, S; McClain, MT; Burke, TW; Petzold, E; Chung, HA; Rivera, GO; Wang, E; Xi, R; Bose, S; Rotstein, T; Nicholson, BP; Chen, T; Henao, R; Sempowski, GD; Denny, TN; De Ussel, MI; Satterwhite, LL; Ko, ER; Ginsburg, GS; Kraft, BD; Tsalik, EL; Shen, X; Woods, CW, Author Correction: Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion., Scientific Reports, vol 13 no. 1 (2023) [10.1038/s41598-023-33323-8] [abs].
  • Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521145] [abs].
  • Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521148] [abs].
  • Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521148.v1] [abs].
  • Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS, Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer (2023) [10.1158/1535-7163.22521145.v1] [abs].